Should I Buy PBM? PBM 2026 Analysis

Should You Buy Psyence Biomedical Ltd (PBM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.720

1 Day change

-6.36%

52 Week Range

85.000

Analysis Updated At

2026/01/26

Psyence Biomedical Ltd (PBM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows significant bearish technical indicators, poor financial performance, and lacks positive catalysts or trading signals. It is better to avoid this stock at the moment.

Technical Analysis

The technical indicators are strongly bearish. The MACD histogram is negative and expanding downward, the RSI is at an extremely oversold level (5.108), and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next major support at 0.308.

Options Data

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

The stock has experienced consistent price declines (-7.91% pre-market, -3.42% regular market, -3.08% post-market). Financial performance is extremely poor, with a significant drop in net income (-632.44% YoY) and EPS (-142.50% YoY). No recent congress trading data or influential figure activity.

Financial Performance

The company's financials for 2026/Q2 show a revenue of 0 with no growth YoY. Net income dropped significantly to -753,254 (-632.44% YoY), and EPS fell to -0.51 (-142.50% YoY). Gross margin remains at 0 with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Analyst Rating

Wall Street analysts forecast PBM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold